Health&Life Co

Health&Life Co Net Debt per Share

The Net Debt per Share of Health&Life Co (1781.TWO) as of Oct 26, 2026 is 4.01 TWD. In the previous year, Net Debt per Share was 4.02 TWD — a change of -0.41% (lower).

Net Debt per Share

4.01TWD

YoY

-0.41%

Last updated:

Net Debt per Share of Health&Life Co is 2025 4.01 TWD. Net Debt per Share of Health&Life Co was 2024 4.02 TWD. It decreases by -0.41% lower compared to the previous year.

The Health&Life Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-1.43 TWD
Jan 1, 2019
-0.28 TWD
Jan 1, 2020
-4.64 TWD
Jan 1, 2021
0.93 TWD
Jan 1, 2022
0.67 TWD
Jan 1, 2023
0.41 TWD
Jan 1, 2024
4.02 TWD
Jan 1, 2025
4.01 TWD
The Health&Life Co Net Debt per Share history
YEARNet Debt per ShareYoY
4.01TWD-0.41%
4.02TWD+892.69%
0.41TWD-39.04%
0.67TWD-28.57%
0.93TWD-120.07%
-4.64TWD+1,564.23%
-0.28TWD-80.50%
-1.43TWD-56.78%
-3.31TWD+2.39%
-3.23TWD-34.56%
-4.94TWD+8.35%
-4.56TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Net Debt per Share of Health&Life Co is 4.01 TWD in 2025.

Net Debt per Share of Health&Life Co changed from 4.02 TWD to 4.01 TWD, representing a -0.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Health&Life Co

All Key Metrics — Health&Life Co